Recent breakthroughs in circulating tumor DNA (ctDNA) technologies present a compelling
opportunity to combine this emerging liquid biopsy approach with the field of radiogenomics …

Guideline-recommended screening programs exist for only a few cancer types. Although all
these programs are understood to lead to reductions in cancer-related mortality, standard-of …

Patients diagnosed with early-stage cancers have a substantially higher chance of survival
than those with late-stage diseases. However, the option for early cancer screening is …

Abstract In the US,< 20% of cancers are diagnosed by standard-of-care (SoC) screening.
Multicancer early detection (MCED) tests offer the opportunity to expand cancer screening …

A multitude of blood-based multicancer early detection (MCED) tests assessing cancer-
related alterations in circulating genomic analytes and other associated signatures are …

Numerous genomic-based early detection screening tests are being developed. These tests
have the potential to revolutionize current single-organ screening paradigms, especially in …

Our Expertise | Multi-cancer early detection | Exact Sciences Exact Sciences logo Health
systems Investor Relations Careers United States Choose your country Select to view the …

The landscape of policies and processes surrounding cancer treatment and financial
aspects of care is evolving, with each new rule affecting oncologists and patients. In a …

MADISON, Wis., December 7, 2023—Exact Sciences, a leading provider of cancer
screening and diagnostic tests, announced today that it awarded $1.3 million to 23 …

At Exact Sciences, we're pioneering a paradigm shift in cancer detection. The
Cancerguard™ test in development is being designed to detect multiple cancers in their …